SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.

ABSTRACT: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adverse cardiovascular events. To address high unmet medical need via improved glycaemic control, several clinical trials have been done to assess the efficacy and safety of SGLT2 inhibitors in combination with insulin therapy in patients with type 1 diabetes. In this Personal View, we summarise data from eight clinical trials of canagliflozin, dapagliflozin, empagliflozin, and sotagliflozin in patients with type 1 diabetes. HbA_1c-lowering efficacy was greatest at 8-12 weeks of therapy, but the magnitude of HbA_1c lowering waned with longer duration of treatment

SUBMITTER: Taylor SI 

PROVIDER: S-EPMC6872914 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature